As someone else said a while back, RVX may be the only stock in history that could get a buy-out offer at $8 and the pps goes down to $4 in the retail market upon the NR. lol

However, I am "probably" buying again into the next pps down turn, there is just too much good smoke around the science. This Mgt team is frustrating, but "even a blind squirrel finds an acorn occasionally" ... there are some big acorns out there, for our blind squirrels in leadership.

Peer-reviewed publishing in Cell, to go with BTD, and safety. BoM2 design looks promising also, with the cards stacked a little better this time toward our previously BoM1 demonstrated strengths and favor.

Something has to give soon, within the next 1-2 years, maybe/hopefully sooner. If I am buying into this technology at well under a buck (U.S.) cuurrently, it is difficult for me to even imagine how I will not get that back (likely a lot more), even if I have to wait 2 more years ... especially with a tax loss credit which might be worth $1-2 pps by itself?

Here's hoping for continued good Covid news/progress, study validation, and the possibility for an attractive "bump" in pps later in 2021 that allows us to make whatever moves feel best for each of us along the way. And of course, a BP deal in some form would be nice sometime this year, as the game of economic chicken plays out.

Frustrated but still optimistic. 

jmho's & glta